## Anna J Lomax

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5309047/publications.pdf

Version: 2024-02-01



ΔΝΝΑΙΙΟΜΑΧ

#	Article	IF	CITATIONS
1	Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with antiâ€PDâ€1 therapy. Internal Medicine Journal, 2019, 49, 1051-1053.	0.5	6
2	Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. Journal of Skin Cancer, 2018, 2018, 1-13.	0.5	21
3	Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician. EMA - Emergency Medicine Australasia, 2017, 29, 245-251.	0.5	25
4	Immunotherapyâ€induced sarcoidosis in patients with melanoma treated with <scp>PD</scp> â€1 checkpoint inhibitors: Case series and immunophenotypic analysis. International Journal of Rheumatic Diseases, 2017, 20, 1277-1285.	0.9	89
5	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncology, The, 2017, 18, 1202-1210.	5.1	211
6	Bullous pemphigoidâ€like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab. Australasian Journal of Dermatology, 2016, 57, 333-335.	0.4	19
7	Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial. Journal of Bone Oncology, 2013, 2, 145-153.	1.0	21